ÇÐȸ¼Ò½Ä
1. Á¦ 6ȸ ÀϹÝÀÎÀ» À§ÇÑ °©»ó¼± ÀÌ¾ß±â ¹× Á¦ 3 ȸ °©»ó¼± ¾ÏȯÀÚ¸¦ À§ÇÑ À§·Î¿Í Èñ¸ÁÀÇ ÄܼƮ – ³ªºñÀÇ ²Þ | |
±Ý³âµµ "Á¦ 6 ȸ ÀϹÝÀÎÀ» À§ÇÑ °©»ó¼± À̾߱â"´Â ÀÛ³â°ú µ¿ÀÏÇÏ°Ô Áö¿ªº°·Î ³ª´©¾î 9°³ Áö¿ª¿¡¼ °ø°³°Á Çü½ÄÀ¸·Î ½Ç½ÃÇÏ¿´½À´Ï´Ù. Çà»ç ÁøÇà ÁÖ°£Àº 2012³â 6¿ù 8ÀϺÎÅÍ 22ÀÏ »çÀÌ·Î °¢ Áö¿ªº°·Î °³ÃֵǾú½À´Ï´Ù. (Âü¿©Áö¿ª: ±¤ÁÖ/´ë±¸/´ëÀüÃæ³²/ºÎ»ê/¼¿ï/¿ï»ê/ÀÎõ/ÀÏ»ê/ÀüºÏ) ¶Ç 2012³âµµ "Á¦ 3 ȸ °©»ó¼± ¾ÏȯÀÚ¸¦ À§ÇÑ À§·Î¿Í Èñ¸ÁÀÇ ÄܼƮ – ³ªºñÀÇ ²Þ"µµ ¿¬¼¼´ëÇб³ ¹éÁֳ⠱â³ä°ü¿¡¼ 2012³â 6¿ù 15ÀÏ ±Ý¿äÀÏ ¿ÀÈÄ ÀÏ°ö½Ã¿¡ ÁøÇàµÇ¾úÀ¸¸ç °©»ó¼±¾ÏÀ¸·Î ¸ñ¼Ò¸®¸¦ ÀÒÀº ÈÄ Çdzª´Â ³ë·ÂÀ¸·Î ÀçÈ°¿¡ ¼º°øÇÑ Å×³Ê ¹èÀçö ±³¼ö µîÀÌ Ã⿬ÇÏ¿© °ü°´µé¿¡°Ô Å« °¨µ¿À» ¾È°Ü ÁÖ¾ú½À´Ï´Ù. Àü±¹ÀûÀ¸·Î 1200¸í ÀÌ»óÀÌ Âü¼®ÇÑ °¡¿îµ¥ ¼º´ëÇÏ°Ô Ä¡·ç¾îÁø À̹ø Çà»ç´Â ¸Å³â ȸ¸¦ °ÅµìÇÒ¼ö·Ï È£ÀÀÀ» ´õÇØ°¡°í ÀÖ½À´Ï´Ù. |
|
2. 2012³â °©»ó¼± ÃÊÀ½ÆÄ ¿¬¼ö°Á | |
´ëÇÑ °©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ¿¡¼ ÁÖÃÖÇÏ´Â 2012³â °©»ó¼± ÃÊÀ½ÆÄ ¿¬¼ö°Á°¡ 2012³â 7¿ù 22ÀÏ ÀÏ¿äÀÏ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø¿¡¼ °³ÃֵǾú½À´Ï´Ù. ±Ý¹ø ¿¬¼ö°Á´ °©»ó¼± ÃÊÀ½ÆÄ ¹× ¼¼Ä§Á¶Á÷°Ë»çÀÇ À̷аú ½ÇÁ¦´Â ¹°·Ð ¾ËÄÚ¿Ã °æÈ¿ä¹ý ¹× ºñ¼ö¼úÀû Ä¡·á µîÀÇ ´Ù¾çÇÑ ÇÁ·Î±×·¥°ú Hands-on programÀ¸·Î ±¸¼ºµÇ¾î 212¸í¿¡ ´ÞÇÏ´Â Âü°¡ÀÚµéÀÇ È£ÆòÀ» ¹Þ¾Ò½À´Ï´Ù. | |
3. ÀþÀº ¿Ü°úÀǸ¦ À§ÇÑ 2012 ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö | |
Á¦ 2ȸ ÀþÀº ¿Ü°úÀǸ¦ À§ÇÑ ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ½ÉÆ÷Áö¾öÀÌ 10¿ù 14ÀÏ ¾ÆÁÖ´ëÇб³ º´¿ø ´ë°´ç¿¡¼ °³ÃֵǾú½À´Ï´Ù. À̹ø ½ÉÆ÷Áö¾öÀº Á¦ 1ȸ ½ÉÆ÷Áö¾ö¿¡ ÀÌ¾î °©»ó¼±³»ºÐºñºÐ¾ßÀÇ ±âº»¼ú±â ±³À°°ú ½Ç¿ëÀûÀÎ ¿äÁ¡ À§ÁÖ·Î ÁøÇàµÇ¾úÀ¸¸ç °ÀÇÀÚ·á´Â ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ ȨÆäÀÌÁö¿¡ ¼ È®ÀÎÀÌ °¡´ÉÇÕ´Ï´Ù. (www.kates.or.kr) | |
4. ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Ãß°èÇмú´ëȸ | |
´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Ãß°èÇмú´ëȸ°¡ 2012³â 11¿ù 30ÀÏ ±Ý¿äÀÏ ´ëÇÑ¿Ü°úÇÐȸ Ãß°è ÅëÇÕÇмú´ëȸ¿Í °°ÀÌ °³ÃֵǾú½À´Ï´Ù. 1³â¿¡ 2ȸ °³ÃֵǴ Çмú´ëȸ´Â ¸Å¹ø ¼öÁØ ³ôÀº ¿¬Á¦¿Í ½Éµµ ±íÀº Åä·ÐÀ¸·Î Âü¼®Àڵ鿡°Ô °©»ó¼± ¹× ³»ºÐºñ¿Ü°ú ºÐ¾ßÀÇ ÃÖ½ÅÁö°ßÀ» ¼Ò°³ÇÏ°í ÀÖ½À´Ï´Ù. À̹ø Ãß°è Çмú´ëȸ¿¡¼´Â USA, University of ChicagoÀÇ Dr. Peter Angelos¸¦ ÇØ¿Ü ¿¬ÀÚ·Î ÃÊûÇÏ¿© Medical Ethics and Medico-Legal Problems in Endocrine Surgery Field¶ó´Â ÁÖÁ¦·Î Ư°À» ÁغñÇÏ¿´°í °©»ó¼± ¼öÁú¾Ï ¹× °©»ó¼± ºÐȾÏÀÇ Ä¡·á¿¡ ´ëÇÑ ½ÉÆ÷Áö¾ö°ú difficult case¿¡ ´ëÇÑ panel discussion µî ´Ùä·Î¿î ÇÁ·Î±×·¥À¸·Î ÁøÇà µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ´ëÇÑ ¿Ü°úÇÐȸ¿¡¼ ÁÖÃÖÇÏ´Â KOSIS 2012¸¦ ÁÖ°üÇÏ¿© USA, Memorial Sloan Kettering Cancer CenterÀÇ Dr. Jatin Shaha µî ¼¼°èÀûÀÎ ´ë°¡µéÀÇ °ÀǸ¦ µéÀ» ±âȸ¸¦ ¸¶·ÃÇÏ¿´½À´Ï´Ù. |
|
5. 2012³â ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Ãß°èÇмú´ëȸ Çмú»ó ¼ö»óÀÚ | |
1) ¸í¹ÎÇмú»ó ÃÖ´Ù³í¹®»ó 1¸í | |
ÃæºÏÀÇ´ë ¿Ü°ú ¹ÚÁø¿ì (Ã¥ÀÓÀúÀÚ) | |
2) ¸í¹ÎÇмú»ó ÃÖ¿ì¼ö³í¹®»ó 2¸í | |
A. °¡ÃµÀÇ´ë ±æº´¿ø ¿Ü°ú Á¤À¯½Â (1ÀúÀÚ)/ÀÌ¿µµ· (Ã¥ÀÓÀúÀÚ) 'Level V Lymph Node Dissection in PTMC Patients: Is This Necessary?' B. µ¿¾ÆÀÇ´ë À̺ñÀÎÈÄ-µÎ°æºÎ¿Ü°ú È«Á¾Ã¶ (1ÀúÀÚ)/º´¸®°ú ±è´ëö (Ã¥ÀÓÀúÀÚ) '¼¼Æ÷ ÈíÀÎ °Ë»ç¿¡¼ Peptide nucleic acid -mediated PCR clamping ¹ýÀ» ÀÌ¿ëÇÑ BRAFV600E À¯ÀüÀÚ º¯ÀÌ °Ë»ç' |
|
3) ¸í¹ÎÇмú»ó ¿ì¼ö³í¹®»ó 4¸í | |
A. Á¶¼±ÀÇ´ë ¿Ü°ú ±èÈ£Áø (1ÀúÀÚ)/±è±Çõ (Ã¥ÀÓÀúÀÚ) 'À¯µÎ»ó °©»ó¼±¾Ï¿¡¼ Cyclin D1, Cytokeratin 7, Cytokeratin 20, VimentinÀÇ ¹ßÇö ¹× ¿¹ÈÄ ÀÎÀÚ¿ÍÀÇ ¿¬°ü¼º¿¡ ´ëÇÑ ºÐ¼®' B. ¿¬¼¼´ë ¿øÁÖÀÇ´ë ¿Ü°ú ±èÁÖÈñ (1ÀúÀÚ)/°¼ºÁØ (Ã¥ÀÓÀúÀÚ) '±¹¼Ò ÁøÇàµÈ ºÐÈ °©»ó¼± À¯µÎ¾Ï¿¡¼ÀÇ ¿ÜºÎ ¹æ»ç¼± Ä¡·áÀÇ ¿ªÇÒ' C. ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø ¿Ü°ú À̹ÎÀç (1ÀúÀÚ)/±è»óÈ¿ (Ã¥ÀÓÀúÀÚ) 'À¯µÎ»ó °©»ó¼±¾Ï¿¡¼ ÃÖ¼Ò °©»ó¼±¿Ü ħ¹üÀÇ ¿¹ÈÄÀÎÀڷμÀÇ À¯¿ë¼º' D. ¼øõÇâÀÇ´ë õ¾Èº´¿ø ¿Ü°ú ¼Û±ÝÁ¾ (1ÀúÀÚ)/±è¼º¿ë (Ã¥ÀÓÀúÀÚ) '¼ö¼ú Àü Ç÷û °©»ó¼± ÀÚ±Ø È£¸£¸ó(TSH)¼öÄ¡¿Í °©»ó¼± À¯µÎ¾Ï°úÀÇ »ó°ü°ü°è' |
|
4) À¯À¯¿¬±¸Çмú»ó 2¸í | |
A. °Ç±¹´ëº´¿ø ¹Ú°æ½Ä (¿¬±¸Ã¥ÀÓÀÚ) (±¹¹®) °©»ó¼± Á¾¾ç ȯÀÚ¿¡¼ÀÇ COX-2 inhibitor ÀÇ ¸ÂÃãÇü ¾à¹°¿ä¹ý Àû¿ëÀ» À§ÇÑ ÀÌ·ÐÀû ±Ù°Å ¹× ±â¹Ý±â¼ú °³¹ß ¿¬±¸ (¿µ¹®) The study for development of rationale for personalized medicine for using COX-2 inhibitor in thyroid cancer and its predictive parameter B. ¼¿ï´ëº´¿ø À̱Ծð (¿¬±¸Ã¥ÀÓÀÚ) (±¹¹®) °©»ó¼± ¿©Æ÷¼±Á¾°ú ¿©Æ÷¾ÏÀÇ ºñ¼ö¼úÀû Áø´ÜÀ» À§ÇÑ Ç÷¾× ³» ºÐÀÚ¸¶Ä¿ Á¦½Ã (¿µ¹®) Screening of peripheral blood biomarkers for non-surgical diagnosis of follicular adenoma and follicular thyroid carcinoma |
|
5) ¿ì¼ö¿¬Á¦¹ßÇ¥»ó | |
1) ¼¿ïÀÇ´ë ¿Ü°ú ±¸µµÈÆ Identification of tumor suppressor gene methylation in peripheral blood of thyroid cancer patients and its correlation with clinicopathologic factors 2) ¾ÆÁÖÀÇ´ë ¿Ü°ú ÀÌÁ¤ÈÆ The significance of the number of metastatic lymph nodes to stratify the risk of recurrence 3) °¡Å縯ÀÇ´ë ¿Ü°ú ÀåÀº¿µ Prognostic value of metastatic lymph node ratio in papillary thyroid carcinoma 4) ¿¬¼¼ÀÇ´ë ¿Ü°ú Á¤¿õÀ± Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma; Comparative analysis after propensity score matching |
|
6) ¿ì¼öÆ÷½ºÅÍ»ó | |
1) ÀÌÈÀÇ´ë ¿Ü°ú ÀÌÁöÇö Is Hashimoto's thyroiditis a prognostic factor for papillary thyroid carcinoma? 2) °æÈñÀÇ´ë ¿Ü°ú ÀåÀçÈÆ BRAF mutation is useful for prediction of poor prognosis of papillary thyroid carcinoma 3) ÀÎÁ¦ÀÇ´ë ¿Ü°ú ¹èµ¿½Ä A randomized controlled trial of ropivacaine injection after robotic thyroidectomy 4) °í·ÁÀÇ´ë ¿Ü°ú ±è¿ì¿µ Outcomes of conservative surgery for papillary thyroid microcarcinoma |
|
6. 2013³â Cadaver Dissection Workshop | |
´ëÇÑ °©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ¿¡¼ ÁÖÃÖÇÏ´Â Á¦6ȸ Fresh Cadaver dissection workshop in endoscopic, robot thyroidectomy and MRND °¡ 2013³â 1¿ù 19ÀÏ Åä¿äÀÏ °í·Á´ëÇб³ ÀÇ°ú´ëÇп¡¼ ¿¸± ¿¹Á¤ÀÔ´Ï´Ù. ±Ý¹ø Cadaver Dissection Workshop ¿¡¼´Â BABA endoscopic/robot thyroidectomy ¹× Gasless axillary endoscopic/robot thyroidectomy ¿Ü¿¡µµ MRND ¹× Laparoscopic adrenalectomy ¿¡ ´ëÇÑ À̷аú ½ÇÀüÀ» ÇÔ²² ¹è¿ï ¼ö ÀÖµµ·Ï ´Ù¾çÇÑ ÇÁ·Î±×·¥À¸·Î ±¸¼ºµÇ¾ú½À´Ï´Ù. | |
7. 2013³â ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Á¤È¸¿ø Á¦µµ ½Ç½Ã | |
´ëÇÑ °©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ¿¡¼´Â ±× µ¿¾È Æò»ýȸ¿ø Á¦µµ¸¦ ÅëÇÏ¿© ȸºñ¸¦ ³½ Æò»ýȸ¿ø¿¡°Ô ÇÐȸ µî·Ïºñ¸¸À» ¹Þ°í ºñȸ¿ø¿¡°Ô ¿¬È¸ºñ ¹× µî·Ïºñ¸¦ ¹Þ´Â Á¦µµ¸¦ ½Ç½ÃÇÏ¿´½À´Ï´Ù. ±×·¯³ª ÇÐȸÀÇ ½ÇÁúÀû ÀÚºñ¿î¿µÀ» À§ÇÏ¿© Æò»ýȸ¿øÁ¦µµ¸¦ ÆóÁöÇÏ°í Á¤È¸¿ø Á¦µµ·Î ÀüȯÇϱâ·Î ÇÏ¿´À¸¸ç ÀÌ´Â ÀÌ»çȸ ÀÓ¿ø ¿Ü¿¡ ¸¹Àº ȸ¿ø ºÐµé²²¼ Âù¼ºÇØÁּ̱⿡ °áÁ¤µÈ »çÇ×ÀÔ´Ï´Ù. 2013³âºÎÅÍ´Â Æò»ýȸ¿øÀº ÀÚµ¿À¸·Î Á¤È¸¿øÀ¸·Î ÀüȯµÇ¸ç ÀÔȸºñ´Â µû·Î ¾ø½À´Ï´Ù. ½Å±Ôȸ¿ø¸¸ ÀÔȸºñ 20¸¸¿øÀ» ³»°Ô µË´Ï´Ù. ´ë½Å ¸ðµç ȸ¿øÀº ¸Å³â 3¸¸¿øÀÇ ¿¬È¸ºñ¸¦ ³»°Ô µË´Ï´Ù. Á¤È¸¿øÀÇ ´ÙÀ½ÀÇ ÇýÅÃÀÌ ÁÖ¾îÁý´Ï´Ù. °¡. ´ëÇѳ»ºÐºñ¿Ü°úÇÐȸÁö ¿¬ 4ȸ ¹ß¼Û ³ª. Çмú´ëȸ µî·Ïºñ °¨¸é (ºñȸ¿ø°ú Æò±Õ 10,000 ~ 20,000¿ø Â÷ÀÌ) ´Ù. ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Á¤È¸¿øÁõ ¹èºÎ ¶ó. ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ ȨÆäÀÌÁöÀÇ ÀÚÀ¯·Î¿î »ç¿ë ¸¶. ÇØ¿ÜÇÐȸ Áö¿ø ´ë»ó ÀÚ°Ý ¹Ù. Çмú»ó ¼ö»ó ´ë»ó ÀÚ°Ý »ç. °¢Á¾ ¿¬±¸ºñ Áö¿ø ÀÚ°Ý ¾Æ. ±âŸ ȸ¿øÀ¸·Î¼ÀÇ ÁöÀ§ À¯Áö ¹× ÇÐȸ·ÎºÎÅÍÀÇ º¸È£ µîÀÔ´Ï´Ù. *3³â °£ ¿¬È¸ºñ ¹Ì ³³ºÎ ½Ã Á¤È¸¿ø ÀÚ°ÝÀÌ ÀϽà Á¤Áö µÉ ¼ö ÀÖ½À´Ï´Ù. |
|
8. 2013 ±¹³» ¹× ÇØ¿ÜÇÐȸ ÇöȲ | |
2013³â ´ëÇÑ°©»ó¼±ÇÐȸ ¿¹Á¤: 2013³â 2¿ù 22ÀÏ – 23ÀÏ Àå¼Ò: ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÄÁº¥¼Ç¼¾ÅÍ (ÄÁº¥¼ÇȦ) 2013³â ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Ãá°èÇмú´ëȸ ¿¹Á¤: 2013³â 4¿ù 6ÀÏ Àå¼Ò: ´ë±¸ ¿µ³²´ëº´¿ø American Association of Endocrine Surgeons ¿¹Á¤: April 12 – 16, 2013 Àå¼Ò: Chicago, Illinois International Association of Endocrine Surgeons ¿¹Á¤: August 25 – 29, 2013 Àå¼Ò: Helsinki, Finland 37th European Thyroid Association ¿¹Á¤: September 7-11, 2013 Àå¼Ò: Leiden, Netherlands 83rd American Thyroid Association ¿¹Á¤: October 16 - 20, 2013 Àå¼Ò: San Juan, Puerto Rico |
|
9. ±âŸ °øÁö»çÇ× | |
1) | ´ëÇÑ °©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ¼Ò½ÄÁö´Â ȸ¿ø »óÈ£°£ÀÇ ±³·ù¿Í Ä£¸ñµµ¸ð, µ¿Á¤ÆľÇ, °øÁö»çÇ× µîÀ» À§ÇØ ¹ßÇàµÇ°í ÀÖ½À´Ï´Ù. ȸ¿øµé°£¿¡ °øÀ¯ÇÏ½Ç »çÇ×ÀÌ ÀÖÀ¸½Å ȸ¿ø²²¼´Â È«º¸À§¿øȸ (ÀÌ»ç Á¤±â¿í surgeonckw@amc.seoul.kr ¶Ç´Â °£»ç ¼ºÅ¿¬ tysung@amc.seoul.kr )·Î ¾ðÁ¦µçÁö ¿¬¶ô Áֽñ⠹ٶø´Ï´Ù. |
2) | ´ëÇÑ °©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ "Korean Association of Thyroid and Endocrine Surgeons (KATES)" °ø½Ä ¸ÞÀÏ°èÁ¤ (kates@kates.or.kr)ÀÌ ¿î¿µµÇ°í ÀÖÀ¸¸ç ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ ºñ¼ (±è°í¿î Tel. 02-3468-3664)°¡ À̸¦ °ü¸®ÇÏ°í ÀÖ½À´Ï´Ù. ¾ÕÀ¸·Îµµ ¸¹Àº ÀÌ¿ë ºÎŹ µå¸³´Ï´Ù. |